首页> 美国卫生研究院文献>British Heart Journal >Implications for present and future applications of the implantable cardioverter-defibrillator resulting from the use of a simple model of cost efficacy.
【2h】

Implications for present and future applications of the implantable cardioverter-defibrillator resulting from the use of a simple model of cost efficacy.

机译:使用成本效益的简单模型对植入式心脏复律除颤器的当前和未来应用具有影响。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

OBJECTIVE--To develop a model to assess the cost-efficacy of the implantable cardioverter defibrillator to prevent sudden death. The model must be sufficiently flexible to allow the use of cost and survival figures derived from different sources. SETTING--The study was conducted in a teaching hospital department of cardiology with experience of 40 implantable cardioverter defibrillator implants and a large database of over 500 survivors of myocardial infarction. PROCEDURE--The basic costs of screening tests, stay in hospital, and purchase of implantable cardioverter defibrillators were derived from St George's Hospital during 1991. To assess the cost-efficacy of various strategies for the use of implantable cardioverter defibrillators, survival data taken from published studies or from our own database. Implications of the national cost of the various strategies were calculated by estimating the number of patients a year requiring implantation of a defibrillator if the strategy was adopted. RESULTS--Use of implantable cardioverter defibrillators in survivors of cardiac arrest costs between 22,400 pounds and 57,000 pounds for each year of life saved. Most of the strategies proposed by the current generation of implantable cardioverter defibrillator trials have cost efficacies in the same range, and adoption of any one of these strategies in the United Kingdom could cost between 2 million pounds and 100 million pounds a year. Future technical and medical developments mean that cost-efficacy may be improved by up to 80%. Due to the limitations of screening tests currently available restriction on the use of implantable cardioverter defibrillators to those groups where it seems highly cost-effective will result in a small impact on overall mortality from sudden cardiac death. CONCLUSION--Present and possible future applications of the implantable cardioverter defibrillator seem expensive when compared with currently accepted treatments. Technical and medical developments are, however, likely to result in a dramatic improvement in cost efficacy over the next few years.
机译:目的-开发一种模型来评估植入式心脏复律除颤器的成本效益,以防止猝死。该模型必须足够灵活,以允许使用来自不同来源的成本和生存数字。地点-该研究是在一家教学医院的心脏病科进行的,具有40种植入式心脏复律除颤器植入物的经验,以及一个包含500多名心肌梗死幸存者的大型数据库。程序-筛查测试,住院和购买植入式心脏复律除颤器的基本费用来自1991年的圣乔治医院。为评估使用植入式心脏复律除颤器的各种策略的成本效益,生存数据取自已发表的研究或来自我们自己的数据库。如果采用该策略,则通过估算每年需要植入除纤颤器的患者人数,可以计算出各种策略对国家成本的影响。结果-植入式心脏复律除颤器在挽救生命的心脏骤停幸存者中的使用每年可节省22,400磅至57,000磅。当前一代植入式心脏复律除颤器试验提出的大多数策略的成本效益都在同一范围内,在英国采用这些策略中的任何一种每年可能要花费200万英镑至1亿英镑。未来的技术和医学发展意味着成本效率可能会提高80%。由于筛查测试的局限性,目前可用的植入式心脏复律除颤器仅限于那些似乎具有高成本效益的人群,这对心脏猝死的总体死亡率影响很小。结论-与目前接受的治疗相比,植入式心脏复律除颤器的当前和未来可能的应用似乎昂贵。然而,技术和医学的发展很可能在未来几年内大大提高成本效益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号